A Wiegering1, K Herrmann, C Bluemel, A K Buck, C-T Germer. 1. Klinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie, Universitätsklinik Würzburg, Oberdürrbacherstr. 2, 97080, Würzburg, Deutschland, wiegering_a@ukw.de.
Abstract
BACKGROUND: Examinations using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) are becoming increasingly more important in clinical practice for the diagnosis and therapy of cancer patients. QUESTION: What role does FDG-PET/CT examination play in the diagnosis and therapy of rectal cancer? RESULTS: The FDG-PET/CT method is especially valuable during postoperative care when a recurrence is suspected. Especially when tumor marker levels rise with no other symptoms, FDG-PET/CT can be used to evaluate unclear lesions in the liver and unclear tissue formations at the surgery site and distinguish between scar tissue and recurring tumors. Currently, there is increasing evidence that a survival prognosis may be possible based on the tracer uptake of FDG-PET/CT. There is also a great interest in the possibility of evaluating the success of neoadjuvant therapy with FDG-PET/CT. DISCUSSION: Despite some limitations FDG-PET/CT plays a significant role in the diagnosis and treatment of patients with rectal cancer.
BACKGROUND: Examinations using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) are becoming increasingly more important in clinical practice for the diagnosis and therapy of cancerpatients. QUESTION: What role does FDG-PET/CT examination play in the diagnosis and therapy of rectal cancer? RESULTS: The FDG-PET/CT method is especially valuable during postoperative care when a recurrence is suspected. Especially when tumor marker levels rise with no other symptoms, FDG-PET/CT can be used to evaluate unclear lesions in the liver and unclear tissue formations at the surgery site and distinguish between scar tissue and recurring tumors. Currently, there is increasing evidence that a survival prognosis may be possible based on the tracer uptake of FDG-PET/CT. There is also a great interest in the possibility of evaluating the success of neoadjuvant therapy with FDG-PET/CT. DISCUSSION: Despite some limitations FDG-PET/CT plays a significant role in the diagnosis and treatment of patients with rectal cancer.
Authors: W Schmiegel; A Reinacher-Schick; D Arnold; U Graeven; V Heinemann; R Porschen; J Riemann; C Rödel; R Sauer; M Wieser; W Schmitt; H-J Schmoll; T Seufferlein; I Kopp; C Pox Journal: Z Gastroenterol Date: 2008-08 Impact factor: 2.000
Authors: Jong Wan Kim; Hyun Chul Kim; Ji Won Park; Sung Chan Park; Dae Kyung Sohn; Hyo Seong Choi; Dae Yong Kim; Hee Jin Chang; Ji Yeon Baek; Sun Young Kim; Seok Ki Kim; Jae Hwan Oh Journal: Int J Colorectal Dis Date: 2013-02-13 Impact factor: 2.571
Authors: Andrew M Scott; Dishan H Gunawardana; Ben Kelley; John G Stuckey; Amanda J Byrne; Jayne E Ramshaw; Michael J Fulham Journal: J Nucl Med Date: 2008-08-14 Impact factor: 10.057
Authors: Susan L Gearhart; Deborah Frassica; Ron Rosen; Michael Choti; Richard Schulick; Richard Wahl Journal: Ann Surg Oncol Date: 2006-01-30 Impact factor: 5.344
Authors: Felipe A Calvo; Marta Domper; Raúl Matute; Raúl Martínez-Lázaro; José A Arranz; Manuel Desco; Emilio Alvarez; José Luis Carreras Journal: Int J Radiat Oncol Biol Phys Date: 2004-02-01 Impact factor: 7.038
Authors: K Davey; A G Heriot; J Mackay; E Drummond; A Hogg; S Ngan; A D Milner; R J Hicks Journal: Dis Colon Rectum Date: 2008-05-07 Impact factor: 4.585